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PEMBANGUNAN TINDAK BALAS BERANTAI POLIMERASE MASA-
NYATA BAGI PENGESANAN AWAL, RAMALAN TINDAKBALAS 
RAWATAN DAN PEMANTAUAN PENYAKIT KANSER PANGKAL 
HIDUNG/ NASOFARINKS (NPC)  
ABSTRAK 
Karsinoma Nasofarinks (NPC) adalah karsinoma sel skuamos tanpa-
limfomatosa yang berlaku pada lapisan sel epitelium yang menutupi permukaan 
nasofarinks. NPC dianggap sebagai cabaran diagnostik bagi doktor kerana kesukaran 
pemeriksaan nasofarinks dan gejala yang tidak spesifik. Virus Epstein – Barr (EBV) 
dikait rapat dengan NPC. Selain itu, delesi 30 bp LMP1 pada EBV didapati 
memainkan peranan penting dalam peningkatan tingkah laku onkogenik pada sel yang 
dijangkiti, seterusnya menghasilkan fenotip tumour-berkaitan EBV yang lebih agresif. 
Oleh itu, kajian ini bertujuan untuk membangunkan kaedah qPCR berasaskan proba 
hidrolisis Taqman yang inovatif untuk mengesan delesi 30 bp LMP1 pada EBV 
menggunakan sampel darah dari pesakit NPC. Kaedah yang dibangunkan ini akan 
membantu doktor dalam diagnosis awal, ramalan tindak balas rawatan, memahami 
sejauh mana keberkesanan rawatan dan pemantauan susulan selepas rawatan pesakit 
NPC. Dalam kaedah i-qPCR yang dibangunkan ini, primer, proba dan penyekat 
degeneratif berbilang titik yang specifik bagi mengesan mutan telah direkabentuk. 
Parameter qPCR berasaskan proba hidrolisis Taqman untuk mengesan delesi 30 bp 
LMP1 pada EBV juga dioptimumkan. Tambahan pula, kawalan dalaman 
diasimilasikan bagi mengetepikan hasil keputusan negatif yang salah. Data demografi 
pesakit NPC dikumpulkan dan digunakan dalam analisis statistik kajian ini. 
Pengesahan ujian dicapai berdasarkan garis panduan MIQE. Kespesifikan analitikal 
bagi kaedah yang telah dibangunkan dilakukan dengan menggunakan pencairan bersiri 
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10 kali ganda MT gBLOCK (DNA sintetik). Kepekaan analitikal dinilai menggunakan 
48 DNA genomik bakteria, kulat dan virus, serta 12 DNA genomik yang telah 
diekstrak daripada tisu biopsi arkib dan sampel aspirasi jarum halus pesakit NPC. 
Penilaian diagnostik kaedah yang dibangunkan dilakukan pada 109 spesimen 
prospektif dari pesakit NPC, pesakit kanser bukan NPC dan individu yang sihat. LOD 
bagi kaedah yang telah dibangunkan ini adalah 173 salinan/ujian. Penilaian diagnostik 
menunjukkan 100% kespesifikan, 83.3% kepekaan, 100% PPV dan 98.7% NPV. 
Hubungan yang signifikan didapati antara ramalan tindak balas rawatan doktor dan 
nilai Cq delesi 30 bp dalam kajian ini (nilai P = 0.033). Kesimpulannya, kajian ini 
berjaya mengembangkan i-qPCR untuk pengesanan awal penanda tumour delesi 30 bp 
dengan kepekaan dan kespesifikan yang tinggi bagi membantu doktor dalam ramalan 
tindak balas rawatan dan menentukan keberkesanan rawatan di kalangan pesakit NPC.  
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DEVELOPMENT OF REAL-TIME PCR ASSAY FOR THE EARLY 
DIAGNOSIS, TREATMENT RESPONSE PREDICTION AND 
MONITORING OF NASOPHARYNGEAL CARCINOMA (NPC) DISEASE 
 
ABSTRACT 
Nasopharyngeal carcinoma (NPC) is a non-lymphomatous squamous cell 
carcinoma that develops in the epithelial cells layer covering the surface of the 
nasopharynx. NPC is considered a diagnostic challenge to clinicians due to the 
difficulty in nasopharynx examination, and non-specific symptoms. The Epstein–Barr 
virus (EBV) is well-associated with NPC. In addition, EBV LMP1 30 bp deletion was 
shown to play a vital role in enhanced oncogenic behaviour of EBV infected cells and 
results in more aggressive EBV-related tumour phenotypes. Therefore, this study 
intended to develop an innovative Taqman hydrolysis probe-based qPCR to detect the 
EBV's LMP1 30 bp deletion using whole blood samples from NPC patients. This 
developed assay will help the clinicians in early diagnosis, treatment response 
prediction, understand the extent of treatment effectiveness, and follow-up monitoring 
of NPC patients after treatment. In this developed i-qPCR, the mutant-specific primers, 
probes and multi-points degenerative blocker were designed. The Taqman hydrolysis 
probe-based qPCR parameters to detect the EBV's LMP1 30 bp deletion were also 
optimised. Internal control (IAC) was incorporated to rule out the false negative result. 
The demographic data of NPC patients were collected and used in the statistical 
analysis of this study. The assay validation was accomplished based on MIQE 
guidelines. The developed assay's analytical sensitivity was performed using 10-fold 
serial dilutions of MT gBLOCK (synthetic DNA). The analytical specificity was 
evaluated using 48 bacterial, fungal and virus genomic DNA and 12 extracted genomic 
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DNA from archived biopsy tissue and fine-needle aspiration samples of NPC patients. 
The diagnostic evaluation of the developed assay was performed on 109 prospective 
specimens from NPC patients, non-NPC cancer patients and healthy individuals. The 
LOD of this developed assay was 173 copies/assay. The diagnostic evaluation showed 
100% specificity, 83.3% sensitivity, 100% PPV and 98.7% NPV. A significant 
association was found between clinician treatment response prediction and Cq values 
of 30 bp deletion in this study (P-value= 0.033). In conclusion, this study was effective 
in developing an i-qPCR assay for early detection of 30 bp deletion tumour marker 
with high specificity and sensitivity, to help clinicians in treatment response 




CHAPTER 1  
 
INTRODUCTION AND LITERATURE REVIEW 
1.1  Epstein Barr virus (EBV) 
Epstein Barr virus (EBV) is also nominated as designated human herpesvirus 
4 (HHV-4), and EBV is a member of the Lymphocryptovirus genus and classified 
within the gammaherpesviruses subfamily and Herpesviridae family (Ooka, 1985; 
Kliszczewska et al., 2017). In 1964, EBV was first discovered in a B lymphocyte cell 
line from African Burkitt’s lymphoma (BL) patient by Epstein, Achong, and Barr 
(Epstein, 1964; Cohen, 2000; Crawford, 2001). In 1968, EBV was discovered as a 
causative agent of heterophile-positive infectious mononucleosis (IM) (Henle et al., 
1968; Cohen, 2000). Two years later, in 1970, EBV DNA was found in tissue samples 
from nasopharyngeal carcinoma (NPC) patients (Zur Hausen et al., 1970; Cohen, 
2000; Young et al., 2016). Moreover, after ten years later, in the 1980s, the association 
between EBV with oral hairy leukoplakia (OHL), in the acquired immunodeficiency 
syndrome (AIDS) and non-Hodgkin’s lymphoma (NHL) patients was found (Ziegler 
et al., 1982; Greenspan et al., 1985). From that time, EBV DNA has been found in 
tissue biopsy samples from different types of cancer such as Hodgkin’s lymphoma 
(HL) and T-cell lymphomas (Jones et al., 1988; Cohen, 2000; Young et al., 2016). 
Recently, EBV is a ubiquitous pathogen that has been estimated to be occurred in more 
than 90% of populations worldwide based on epidemiological studies (Smatti et al., 
2018). 
Two main EBV genotypes were detected in human, type 1 (EBV-1) and type 2 
(EBV-2) (also known as types A and B, respectively), distinguished by the differences 




3B, and EBNA-3C) (IARC Working Group on the Evaluation, 2012; Smatti et al., 
2018). Due to the homology of EBNA-2 between EBV-1 and EBV-2 reveals only 
54%, distinguished between EBV types 1 and 2 can be done based on EBNA-2 (Smatti 
et al., 2018). 
The ability of EBV-2 to immortalize and convert B cells into lymphoblastoid 
cell lines (LCL) was shown to be less efficient than EBV-1 and EBV-2 infected LCL 
was less variability than EBV-1 infected LCL (IARC Working Group on the 
Evaluation, 2012; Zanella et al., 2019). A distinctive geographical distribution was 
discovered between EBV-1 and EBV-2. The EBV-1 is the most prevalent globally, 
predominantly in North and South America, Asia, and Europe. However, EBV-2 is 
more frequent in Papua New Guinea, Alaska, and Central Africa, with a higher 
frequency was reported in Kenya. In fact, in these areas, dual infections with these 
EBV types were also discovered (Zanella et al., 2019) 
1.2  EBV structure and genome 
The EBV virion is approximately 122 – 180 nm in diameter and the EBV virion 
structure is like other herpesviruses structures (Kliszczewska et al., 2017; Smatti et al., 
2018).  EBV genome is linear, double-stranded DNA with a genome size of around 
172-kb DNA molecule that encodes more than 85 genes (Thompson et al., 2004; 
Santpere et al., 2014).  The EBV DNA is wrapped with an inner toroid-shaped protein 
core, a nucleocapsid with 162 capsomers with about 100 nm in diameter, a protein 
tegument between the nucleocapsid and the envelope, and an outer envelope with 
external virus-encoded glycoprotein spikes for binding of cell surface receptor (Figure 
1.1) (Thompson et al., 2004; Kieff et al., 2007; IARC Working Group on the 




The EBV genome includes series of around 3.1 kbp internal repeat sequences 
and around 0.54 kbp terminal direct repeats at both ends that also assist in dividing the 
EBV genome into unique sequence domains (short and long; US and UL, respectively) 
with the highest coding capacity (Figure 1.2) (Cheung et al., 1982; Thompson et al., 
2004; Arvin et al., 2007). In addition, these repetitions can assist as an indicator for 
the source of EBV whether the infected cells were derived from the same progenitor 


















Figure 1.1 Structure of EBV. The main components of EBV virion are the 
inner EBV genome core, nucleocapsid, an amorphous tegument, and an outer 

















Figure 1.2 The Epstein–Barr virus genome. 
A. Epstein–Barr virus (EBV) virion electron micrograph. 
B. Diagram represents the EBV latent genes on the double-stranded viral DNA 
episome, EBV latent genes' transcription, and location. The orange color represents 
the origin of plasmid replication (OriP). The large green solid arrows represent each 
latent protein-encoding exon, and the arrows indicate the direction of genes 
transcription into EBV latent proteins. The latent proteins consist of the six nuclear 
antigens (EBNAs 1, 2, 3A, 3B and 3C, and EBNA-LP) and the three latent membrane 
proteins (LMP1, 2A and 2B). The transcription of all the EBNAs is started by either 
the Cp or Wp and Qp promoter. The top arrows (blue) represent EBER1 and EBER2 
(the highly transcribed non-polyadenylated RNAs); their transcription is a consistent 













The major EBV capsid that is purified from enveloped virus consists of 68 kDa 
portal protein, 18 kDa small capsid protein, 30 kDa minor capsid protein, 40 kDa 
minor capsid protein-binding protein and 155 kDa major capsid protein, all in the 
expected ratios, based on 12 portal molecules per virion (Kieff et al., 2007). The EBV 
tegument consists of the 140 kDa large tegument protein binding protein (BOLF1), 15 
kDa myristylated protein (BBLF1), 58 kDa packaging protein (BGLF1), 350 kDa large 
tegument protein (BPLF1), 32 kDa myristylated protein binding protein (BGLF2), 27 
kDa palmitylated protein (BSRF1), 47 kDa TS kinase (BGLF4) and 58 kDa capsid 
associated protein (BVRF1), which are prevalent elements of Herpesvirus teguments 
(Kieff et al., 2007). In addition, EBV has a 42 kDa BKRF4, 72 kDa BRRF2, 19 kDa 
BLRF2, 54 kDa BDLF2, 140 kDa major tegument protein (BNRF1), which are also 
specific to gammaherpesvirus (Kieff et al., 2007). Moreover, different components in 
EBV tegument such as Hsp90, Cofilin, actin, HSP70, enolase and β-tubulin are also 
significant and probably correlated to cytoplasmic re-envelopment (Kieff et al., 2007). 
EBV has several major envelope glycoproteins components which are gp78 (BILF2), 
gH (BXLF2), gp350 (BLLF1), gB-N, gB-C, gp42 (BZLF2), gp150 (BDLF3), gM 
(BBRF3), full-length gB (BALF4), gN (BLRF1), and gL (BKRF2) (Kieff et al., 2007). 
However, the gp350/220 is considered a major envelope protein that played an 
important role in B lymphocyte infection by binding gp350/220 with complement 
receptor type 2 (CR 2 or CD21) molecule (Chandran et al., 2007). 
In 1982, the partial sequence (some small fragments) of B95-8 EBV was 
published (Cheung et al., 1982; Tzellos et al., 2012), but in 1984, the first complete 
EBV sequence of the B95-8 strain (accession number V01555) was published based 




library (Baer et al., 1984; Tzellos et al., 2012). The BamHI-restriction fragments map 
was used to establish the nomenclature of the EBV open reading frames, where based 
on the sizes of the found fragments, these fragments were ordered in descending order 
from A to Z, which were also classified into latent or lyric genes (Figure 1.3) (Smatti 






















Figure 1.3 BamHI restriction-endonuclease map of prototype B95.8 
genome with open reading frames location for the EBV latent proteins. The BamHI 
fragments are designated based on their size, from A (the largest) to Z (the smallest) 
in alphabetical order. The purple colour represents the TRs of the EBV genome at 

































During the EBV infection of the cell, the EBV DNA becomes a circular 
episome by joining its terminal repeats (TRs), based on the number of TRs in the 
parental genome. Generally, the EBV progeny episomes have a comparable number 
of TRs to the parent genome. Although, during EBV DNA replication, difference in 
the numbers of TRs can be added to the termini of the EBV genome. During the latent 
infection, future EBV episomes’ generations will have the same number of TRs. 
Therefore, the numbers of latently infected cells’ TRs can help determine the common 
progenitor, either the cancer cells derived from a single cancer-infected progenitor or 
multiple progenitors (Thompson et al., 2004 ; Kieff et al., 2007). However, in the lytic 
phase, EBV DNA is in the linear form during the integration with chromosomes 
(Kliszczewska et al., 2017). 
1.3  EBV transmission and life cycle 
The oral route is the main route of transmission of the EBV (Smatti et al., 
2018). However, the EBV transmission through blood transfusion and organ 
transplantation was also reported (Cen et al., 1991; Alfieri et al., 1996; Hanto et al., 
1981; White et al., 2019).  
The transmission of EBV usually occurs through the saliva. Afterward, EBV 
enters the epithelium layer of the Waldeyer tonsillar ring situated in the oropharynx. 
The virus replication will start during the lytic phase of infection (Smatti et al., 2018).  
Subsequently, while B lymphocytes move close to the tonsil epithelial cell, the 
infection of naive B lymphocytes in the underlying lymphoid tissues occurs. The naive 
B lymphocytes transform to activated lymphoblasts. Then these cells migrate to the 
lymph node follicle where the reaction in the follicle germinal center will initiate 




latent membrane proteins (LMP1, LMP2A, and LMP2B) and the EBV nuclear 
antigens (EBNA1, EBNA 2, EBNA3A, EBNA3B, EBNA3C, and EBNA-LP) are 
expressed, and adversely autoregulate the growth of EBV (Young et al., 2004; Smatti 
et al., 2018).   
Then type II latency program is started (only EBNA1, the EBERs (EBV-
encoded RNA), the BARTs, LMP1, and LMP2A are expressed) and subsequently, the 
infected B cell leaves as memory B lymphocytes from the germinal center. Afterward, 
the “Latency 0” phase begins where the expression of all the viral proteins in the 
memory B lymphocytes will be suppressed. However, latency type I program will be 
initiated if only the EBNA-1 gene is expressed during the division of these memory B 
lymphocytes (Thorley-Lawson et al., 2008; IARC Working Group on the Evaluation, 
2012).  
Moreover, the infected memory B lymphocytes can also eventually return to 
the tonsils, where they sometimes go through plasma-cell differentiation, which induce 
more viral replication and thus cause the infection of other B lymphocytes as well as 
may be released into saliva and thus transmitting the EBV virus to other individuals 


























Usually, the primary infection arising during childhood is asymptomatic, while 
in certain developing countries, IM occasionally appears in adolescents who get delay 
EBV infection. In addition, acute IM patients were found to have high titers of 
infectious EBV, where new EBV virion shed in the throat from the lytic infection 
phase at oropharyngeal sites and can easily be transmitted to the new susceptible 
individuals during persistent lytic infection (Young et al.,, 2004).   
EBV virus infects the B lymphocytes by the binding of the viral envelope 
glycoprotein gp350/220 to CD21 and by the binding of gp42 (second glycoprotein) to 
human leukocyte antigen (HLA) (class II molecules) as a co-receptor. While, the EBV 
Infection of other cells such as epithelial cells are much less effective and occurs by 
separate, as yet poorly defined pathways (Borza et al., 2002; Prabhu et al., 2016).  In 
addition, a mechanism involving two other viral glycoproteins, such as gp85 and gp25, 
can be used to bind the EBV virion envelope to the host cell membrane. (Li et al., 
1995; Prabhu et al., 2016). However, the exact route of EBV entry into memory cells 
is still a matter of much debate.  
Current proof suggests that in healthy chronic virus carriers, the EBV infection 
is mostly limited to B cells. However, the EBV virus also can be detected in epithelial 
cells in certain cases. The epithelial cells' role in EBV infection is mostly considered 
a site for EBV replication and amplification instead of considering these cells as a site 
of stable latent EBV infection, but until now still questionable (IARC Working Group 
on the Evaluation, 2012; Prabhu et al., 2016). In addition, recent studies have shown 
that the EBV can also infect monocytes/macrophages, smooth muscle cells, T 
lymphocytes, natural killer (NK) cells, and endothelial cells rather than epithelial cells 




EBV in some T-cell lymphomas and other diseases, such as OHL in 
immunocompromised, gastric carcinomas and nasopharyngeal patients (Kieff et al., 
2007; Prabhu et al., 2016). 
T lymphocytes are responsible for removing newly EBV infected cells and for 
managing the infection throughout the primary infection. However, during latency, the 
EBV is protected from the immune system as it stays silenced in the resting memory 
B lymphocytes without expressing any EBV protein. (Smatti et al., 2018). 
1.4  EBV infection stages  
There are two alternative phases of EBV in cells: latent or lytic (Murata et al., 
2014). After B cell infection, the linear EBV genome transforms to circular (episome). 
Episomes are existing as circular genetic elements inside the host cell’s nucleus that 
are closely associated with, but not integrated into, the host DNA. During latent 
infection, episomes are replicated during S phase, but new viral particles are not 
produced and the infected cell survives (Serquina et al., 2017). It usually remains in 
the latent phase inside the infected B cells.  However, only a small percentage will be 
spontaneously activated among the latently infected B lymphocytes, and the lytic 
phase will start (Cohen, 2000). 
1.4.1  EBV lytic infection 
EBV lytic replication is required for virus spreading from host to host and from 
cell to cell and can be occurred in both B cells and epithelial cells (Drouet, 2019). Lytic 
replication is initiated by oriLyt replication origin, which encodes DNA polymerase 





EBV is occasionally activated and replicated in latently infected B cells of most 
asymptomatic EBV infected carriers, followed by EBV virion can be detected in oral 
secretions. The replication process produces new EBV virions called EBV lytic 
replication (Faulkner et al., 2000; Tsurumi et al., 2005). In addition, the reactivation 
process means a switchover from the latent to lytic cycle (Figure 1.5) (Miller et al., 
2007; Murata et al., 2014). However, the mechanism of triggering EBV reactivation 
by physiological stimuli in vivo is not clearly understood. However, in vitro, the EBV 
reactivation process can be elicited by treating with some biological or chemical 
reagents, such as TPA (12-O-tetradecanoylphorbol-13-acetate), calcium ionophore, 
TGF-β (Transforming growth factor-beta), anti-Ig (anti-immunoglobulin) and sodium 
butyrate. This stimulation leads to the expression of two viral (immediate-early) IE 
genes that are known as BZLF1 (BamHI Z fragment leftward open reading frame 1) 
(which encodes transactivators proteins such as Zta, Z, ZEBRA, and EB1) and BRLF1 
(which encodes transactivators proteins such as Rta, R, and EB2) (Miller et al., 2007; 
Murata et al., 2014). 
It is well known that EBV expresses approximately 90 proteins during lytic 
replication. They are classified as IE, early (E) and late (L) proteins (Figure 1.5). After 
EBV infection, the expression of IE and E proteins will occur in the presence of protein 
synthesis inhibitors and viral DNA synthesis inhibitors, respectively. However, in the 
presence of these inhibitors, the L proteins will not express. IE proteins are 
transactivator proteins which play a role in triggering the early proteins expression in 
the virus, including enzymes that are important in virus DNA replication. During the 
late phase of the lytic cycle, the expression of L proteins that are structural proteins 




the release of EBV infectious virions (Cohen, 2000; Young et al., 2007). However, the 
control of both BRLF1 and BZLF1 gene transcription is required to have a balance 






















1.4.2  EBV latent infection 
The persistence of EBV without active EBV production occurs mostly within 
resting memory B cells in the human body and also it is possible to occur in epithelial 
cells (Cohen, 2000; Odumade et al., 2011). In addition, it was reported that 1 to 50 B 
cells per million are carrying the EBV genome in the blood circulation of normal 
adults, and the number of latently infected B cells stays constant throughout the years 
(Babcock et al., 1998; Cohen, 2000). It is generally believed that EBV genomes can 
persist as episomes or/and as integrated DNA in latently infected B cells (Kieff et al., 
1982; Kieff et al., 1985; Odumade et al., 2011). 
During latent EBV infection in B cells, only a limited set (⁓10) of nearly 100 
viral genes (expresses during replication) are expressed in vitro (Sixbey et al., 1983; 
Cohen, 2000). The replication of EBV episomal genome occurs once per cell cycle via 
the host DNA polymerase and the oriP replication origin, and also there is no 
production of progeny EBV virus in this phase (Tsurumi et al., 2005; Drouet, 2019). 
In these latently infected B cells in vitro, two types of non-translated type of EBERs, 
six EBV nuclear antigens (EBNA1, EBNA2, EBNA3A, EBNA3B, EBNA3C, EBNA 
leader protein (EBNA-LP)), BARTs from the BamHI A region (Bam A) of EBV 
genome, microRNAs (miRNAs) and three latent membrane proteins (LMP1, LMP2A 
and LMP2B) are expressed (Cohen, 2000; Young et al., 2007; Odumade et al., 2011; 
Yin et al., 2019). 
Therefore, EBV can persist over the life inside the infected B cells and avoid 
immune system detection during the latent phase (Knipe et al., 2013; Drouet, 2019). 
In immune-competent individuals, a cell-mediated response such as EBV-specific T 




B cells by targeting both lytic and latent antigens, prevent the outgrowth and 
containing the reactivation of EBV infected latent B cells (Rickinson et al., 2014). 
Thus, in congenital or acquired immunosuppressed individuals who get EBV infection 
are highly vulnerable to EBV reactivation and malignant transformation (Cesarman, 
2011; Dierickx et al., 2018). Furthermore, EBV infected patients who have organ/stem 
cell transplantation and was treated with immunosuppressive drugs are at high risk of 
developing the posttransplant lymphoproliferative disorder (PTLD), which is a 
serious, often fatal B-cell lymphoproliferative disease (LPD) complication after 
transplantation, and also may sometimes promote the development of NHL (Dierickx 
et al., 2018; Drouet, 2019). 
 EBV latency patterns  
In vitro, such as in Burkitt’s tumour cell lines and EBV-immortalized LCLs 
and also in vivo, at least three different latency programs were found to be expressed 
(Thorley-Lawson et al., 2004; Yin et al., 2019). During these different latency 
programs, in dividing memory cells, the EBV genome will be multiplied (type I), B-
cell differentiation will be induced (type II), naïve B cells will be activated (type III), 
or the expression of all gene will be entirely restricted in a specific manner (Table 1.1) 
(Thorley-Lawson et al., 2004; Kimura et al., 2008; Odumade et al., 2011).  
Latency 0 characterizes by a very limited spectrum of latent EBV gene 
expression in memory B cells, namely EBERs and BARTs transcripts and founds in 
healthy carriers (Kimura et al., 2008; Kimura et al., 2013). However, In EBV-
associated diseases, different EBV latency programs can detect, which are classified 
into latency I, II and III as shown in Table 1.1 (Gulley, 2001; Young et al., 2007; 




only a restricted spectrum of EBV latent genes expresses, such as EBV EBNA1, 
LMP2A, BARTs and EBERs. However, latency type II associates with HL, T cell 
lymphoma and NPC. The expression of EBNA1, LMP1, LMP2, BARTs, and EBERs 
is detected. In contrast, all latency genes are expressed in latency type III, include 
EBNAs (1, 2, 3A, 3B, 3C, -LP), the LMPs (1, 2A, 2B), BARTs and EBER (Gulley, 
2001; Young et al., 2007; Kimura et al., 2008;). 
 The latency III program is usually seen in LCLs and associates with acute IM, 
lymphoproliferative disorders, and immunosuppressed states, such as in PTLD or 
AIDS patients (Gulley, 2001; Kimura et al., 2008). However, the expression pattern 
of EBV latent genes can be different in the same EBV infected patient among different 
B cell subsets or even in the same tissue. Hence, the classification of EBV latency 
patterns into four latency programs are not restricted and in different EBV-associated 
disease, heterogeneous patterns were detected. Moreover, within the same EBV 
infected individual or even in the same tissue, both lytic and latent infections were 
reported (Kimura et al., 2008; Kimura et al., 2013). For example, in IM, both latent 
infection of latency III program in EBV infected B cells and lytic infection of plasma 
cells or epithelial cells were reported (Yoshioka et al., 2001; Kimura et al., 2008;). In 
addition, in NPC, the majority of the cells are detected with latent infection of latency 
II program and few cells may progress to lytic infection (Brooks et al., 1992; Kimura 







       Table 1.1    The EBV proteins’ function, EBV latency pattern and associated 
malignancy. 
 
 Footnote: EBV, Epstein–Barr virus; EBNA, Epstein-Barr virus nuclear antigen; BARTs, 
BamHI A rightward fragments; LMP, latent membrane protein; EBERs, EBV-encoded 
small RNAs; NK cells, natural killer cells; NK/T cell, nasal natural killer (NK)/T-cell; 
MNCs, mononuclear cells; WBC, white blood; IM, infectious mononucleosis; NPC, 







1.4.3  EBV-associated diseases 
The current estimation has shown that EBV causes 200,000 new cancer cases 
yearly (∼2% of cancers worldwide) (Cancer Research UK) (Al Moustafa et al., 2018). 
In 2009, the International Agency for Research on Cancer review (IARC Working 
Group on the Evaluation, 2012) classified EBV as group 1 carcinogenic that has an 
important role in carcinogenesis of several EBV- associated carcinomas (Bouvard et 
al.,, 2009; Prabhu et al., 2016).  It has been shown that in culture, EBV immortalizes 
normal B cells; the expression of different EBV latent gene products in all EBV-
associated carcinomas; and, at the molecular level, the expression of encoded latent 
gene products during latent viral infection will induce block apoptosis, cell 
prolifertion, modulate cell migration, tumour maintenance, cell progression and 
growth. Moreover, these events can be happened before or during cancer beginning 
(Prabhu et al., 2016). 
Approximately, 95% of the world’s population are asymptomatic life-long 
EBV carriers and most of them after getting EBV infection, they will obtain adaptive 
immunity (Jain et al., 2011; Chijioke et al., 2013). However, infants gain the immunity 
from maternal antibody, hence after this protection disappears, the infants will become 
highly suscepatible to EBV infection (Ebell, 2004; Jain et al., 2011).  In normal healthy 
carriers, EBV persist for long term inside in the memory B-cells and the reactivation 
for latent EBV will contribute to EBV-associated disease and carcinomas. The primary 
infection in majority of children usually is asymptomatic or similar to the other mild 
disease of childhood (Hjalgrim et al., 2007; Jain et al., 2011).  However, when the 
adolescence or teenagers get the primary infection, IM will be resulted in 35% to 69% 




EBV is best known as causative agent for IM (commonly known as kissing disease 
synonyms, Pfeiffer's disease, Filatov's disease, glandular fever or “mono” in North 
America) (Jain et al., 2011; Ali et al., 2015; Shannon-Lowe et al., 2019).  
In addition, Previous reports have detected that particular EBV-latency 
programs are shown in numerous benign and neoplastic diseases (Table 1.2), including 
those of a lymphoid form such as IM, PTLD, HL (Salehiniya et al., 2018), BL, and T-
cell lymphomas and those of an epithelial form such as OHL, NPC, 
lymphoepithelioma-like carcinomas, and gastric carcinoma (Gulley, 2001; Ali et al., 
2015; Elgui de Oliveira et al., 2016).  
Moreover, EBV association with leiomyosarcomas such as smooth muscle 
cells-derived sarcoma in immunocompromised patients, central nervous system 
lymphomas associated with HIV and with autoimmune diseases such as 
dermatomyositis, rheumatoid arthritis, Sjogren’s syndrome, systemic lupus 
erythematosus, and multiple sclerosis have been reported (Table 1.2) (Niedobitek et 
al.,  2001; Jain et al., 2011; Fujiwara et al., 2015; Draborg et al., 2016; Prabhu et al.,  
2016). The association between EBV and breast, prostate, cervical, oral squamous cell 
(OSC) and salivary gland carcinomas was reported, while limited or no association 
between EBV and lung, testis, leukaemia and multiple myeloma was detected (IARC 
Working Group on the Evaluation, 2012; Shi et al., 2016; Teow et al., 2017a). The 
investigation of patients with EBV-infected carcinomas has provided a sensible degree 
of evidence that EBV was present before neoplastic transformation, which highlights 
the requirement of further studies to better understand the extent of EBV involvement 




Table 1.2 Diseases associated with EBV infection. 




Autoimmune disease Multiple sclerosis 99 (Pender, 2004) 
Systemic lupus 
erythematous 
99 (Pender, 2004) 
Rheumatoid arthritis 88 (Pender, 2004) 
Sjogren’s syndrome 57 (Fujiwara et al., 2015) 





>99 (Gulley et al., 2008) 
Oral hairy leukoplakia >95 (Gulley et al., 2008) 
Chronic active EBV 
infection 
100 (Gulley et al., 2008) 
Nasopharyngeal 
carcinoma 
Non-keratinizing 100 (Chang et al., 2005b) 
Keratinizing 30-100 (Chang et al., 2005b) 
Gastric carcinoma UCNT 100 (Chang et al., 2005b) 
Adenocarcinoma 5-15 (Chang et al., 2005b) 
Non-Hodgkin lymphoma and related neoplasms 
BL Endemic 100 (Shannon-Lowe et al., 
2017) 
Sporadic 10-80 (Shannon-Lowe et al., 
2017) 





Post-transplant >90 (Shannon-Lowe et al., 
2017) 
HIV-related >90 (Shannon-Lowe et al., 
2017) 
DLBCL NOS 10 (Shannon-Lowe et al., 
2017) 
PAL 100 Shannon-Lowe et al., 
2017) 




d B lymphomas 
Plasmablastic 
lymphoma 



























Table 1.2  Continued.  
 
Hodgkin lymphoma 
NLPHL - <4 (usually 
absent) 




All subtypes 40 (Marshall-Andon et 
al., 2017) 
Nodular sclerosis 10-40 (variably 
present) 
(Shannon-Lowe et al., 
2017; Carbone et al., 
2018) 
Mixed cellularity 70-80 (usually 
present) 
(Shannon-Lowe et al., 
2017; Carbone et al., 
2018) 
Lymphocyte depleted 10-50 (variably 
present) 
(Shannon-Lowe et al., 
2017; Carbone et al., 
2018) 
Lymphocyte rich 30-60 (variably 
present) 
(Shannon-Lowe et al., 
2017; Carbone et al., 
2018) 
HIV-related >90 (Shannon-Lowe et al., 
2017; Carbone et al., 
2018) 
Other types of cancers 
Salivary gland 
carcinoma 
- 44 (Mozaffari et al., 
2017) 
Cervical carcinoma - 43.63 (Vranic et al., 2018) 
Breast cancer 







(Grinstein et al., 2002; 
Whitaker et al., 2013; 
Shi et al., 2016) 
ESCC - 6.5 (Yanai et al., 2003) 
OSCC - 5.03 (She et al., 2017) 
Footnote: XLP, X-linked lymphoproliferative disease; PAL, pyothorax-associated 
lymphoma; CAEBV, chronic active EBV infection; NOS, not otherwise specified; 
NK/T-cell, nasal natural killer /T-cell; HIV, Human immunodeficiency virus; AIDS, 
acquired immune deficiency syndrome; BL, Burkitt lymphoma; DLBCL, Diffuse 
large B cell lymphoma; UCNT, undifferentiated carcinomas of nasopharyngeal type; 
NLPHL, nodular lymphocyte-predominant Hodgkin’s lymphoma; ESCC, Esophageal 
squamous cell carcinoma; OSCC, Oral squamous cell   carcinoma. 
 
 
1.5  Nasopharyngeal carcinoma (NPC) 
Nasopharyngeal carcinoma (NPC) is a non-lymphomatous squamous cell 




nasopharynx (Brennan, 2006; Tabuchi et al., 2011). In 1921, the first description of 
NPC was defined by Regaud and Schmincke (Regaud  et al., 1921; Schmincke, 1921; 
Brennan, 2006).  
This cancer commonly seen in Fossa of Rosenmüller (FOR) (pharyngeal 
recess) and demonstrates different degrees of differentiation (Shamet et al., 1990; 
Tabuchi et al., 2011). NPC is a distinct form of head and neck cancer that differs from 
other types of upper aerodigestive tract in terms of its etiology, clinical presentation, 
pathology, geographical and racial distribution and response to treatment (Tabuchi et 
al.,  2011; Lao et al., 2020). 
1.5.1  Epidemiology of NPC  
Globally, NPC is an uncommon malignancy with an occurrence rate of usually 
< 1 per 100,000 person-years, but regions with high incidence are in southern China 
(e.g., Cantonese), Southeast Asia (e.g., Sarawak Bidayuh), North Africa and the Arctic 
(e.g., Inuit, Alaska native) (Figure 1.6 A). At the age-standardized incidence rate 
(ASR) for males, the prevalence in these populations are 100 times higher than in other 
ethnic groups. Approximately 129,000 new cases/year are reported in the world 
(Figure 1.6 B), with > 70% reported in Eastern and South-Eastern Asia (Chen et al., 
2019; Rickinson et al.,  2019). According to the International Organization for Cancer 
Research study in 2008, more than 80 % of NPC patients are in Asia and just 5 % of 
NPC patients are registered in Europe. Specifically, 71 % of new NPC cases are 
registered in East and South East Asia and 29 % are diagnosed in South and Central 
Asia and North and East Africa (Chang et al., 2006a). In 2012, ⁓ 86,000 NPC cases 
were diagnosed worldwide and the reported number of deaths exceeded 50,000, 
